Meador Vincent, Jordan William, Zimmermann John
Eli Lilly & Company, Greenfield Laboratories, 2001 East Main Street, Greenfield, IN 46140, USA.
Curr Opin Drug Discov Devel. 2002 Jan;5(1):72-8.
Lead optimization requires toxicity screening strategies to select a compound with a high likelihood of successful development. As numerous compounds need to be screened and resources to direct toward any single compound are limited, short turnaround times to generate and interpret data are needed. Utilization of in vivo toxicity screens is necessary for an effective screening strategy, however, if not appropriately implemented, they may consume excessive resources and prolong selection of a developable compound. Optimization of in vivo studies requires identifying effective placement into the screening strategy, selecting the appropriate study designs, implementing processes that allow rapid data generation and interpretation, and understanding the utilities of in vivo data. When implemented, an effective, high-throughput screening strategy will utilize adequate but minimal amounts of resources, and will prioritize processing near technical time limits. These require generating only the data from which decisions will be made and can be best achieved using as few animals as possible per study.
先导化合物优化需要毒性筛选策略来选择具有高成功开发可能性的化合物。由于需要筛选大量化合物,且用于任何单一化合物的资源有限,因此需要短周转时间来生成和解释数据。体内毒性筛选对于有效的筛选策略是必要的,然而,如果实施不当,它们可能会消耗过多资源并延长可开发化合物的选择时间。体内研究的优化需要确定在筛选策略中的有效位置,选择合适的研究设计,实施能够快速生成和解释数据的流程,以及理解体内数据的效用。实施有效的高通量筛选策略时,将利用适量但最少的资源,并将在接近技术时间限制的情况下优先进行处理。这需要仅生成将据此做出决策的数据,并且每个研究尽可能少用动物才能最好地实现这一点。